Article

Participation in physical activity for people with Multiple sclerosis
(MS) is important but can be difficult to sustain long-term. Facilitators for
long-term adherence include choice over activity and control over level of
engagement, coupled with support, advice and encouragement from a
physiotherapist. This is the basis of Blue Prescription, a novel physiotherapy
approach aimed at optimising long-term adherence with physical activity. We
evaluated the feasibility and short-term benefits of Blue Prescription in people
with MS. METHODS: Twenty-seven people with MS (mean age: 51 +/- 11 years, with a
range of MS type and disability) were assessed at baseline and immediately
post-intervention with the MS Impact Scale, MS Self-efficacy Scale, and European
Quality of Life Questionnaire. Change in outcomes were analysed with Wilcoxon
signed ranks tests. RESULTS: All participants, irrespective of level of
disability, were able to choose a physical activity and to engage in it. The
physical component MS Impact Scale score significantly improved by a median
change of 6.5 (95% CI = -10.5 to -2.0; p = 0.007; effect size = 0.38). There were
no other significant changes in outcomes. CONCLUSION: Blue Prescription appears
feasible and potentially beneficial, particularly in reducing the negative
impacts of MS upon individuals, and thus warrants further evaluation.

Langue : ANGLAIS